This is a pharmaceutical company formed to serve people who have rear health conditions with its operations concentrated in the United Kingdom but also having presence in the United States. It was founded in 1986 and later in January 2019 was acquired by Takeda Pharmaceutical Company (based in Japan) for $62B. Its headquarters in the UK is in Basingstoke, Hampshire, England, and its shares trade on the London Stock Exchange. In the US, the group’s off-site offices are in Cambridge, Illinois, Chicago, and Massachusetts. It has operations in Zug, Switzerland, and in Dublin, Ireland, as well.

The company’s products were distributed worldwide in over 100 countries. It uses biotechnology, with its areas of focus being Immunology, Neuroscience, and Hematology, Lysosomal Storage Disorders, Endocrine Angioedema, and Gastrointestinal disorders. It is also venturing in Oncology and Ophthalmology. The group seeks to give opportunities to patients with life-threatening conditions to have an alternative medical way of living and thus possibly have an extension of their lives.

Latest Shire News

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.